Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
复制标题
重组仙台病毒作为呼吸道合胞病毒的新型候选疫苗。
DOI：
10.1089/vim.2005.18.255
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Slobod,KarenS
中科院分区：
文献类型：
--
作者：
Takimoto,Toru;Hurwitz,JuliaL;Zhan,Xiaoyan;Krishnamurthy,Sateesh;Prouser,Cecilia;Brown,Brita;Coleclough,Chris;Boyd,Kelli;Scroggs,RuthA;Portner,Allen;Slobod,KarenS
呼吸道合胞病毒（RSV）是最重要和最严重的儿科呼吸道疾病之一，但经过四十多年的研究，仍然没有有效的疫苗。本文综述了免疫应答在降低疾病严重程度中的作用;回顾了RSV疫苗开发的历史;并主张仙台病毒（一种鼠副粘病毒）作为异种疫苗载体用于递送RSV抗原的潜在效用。使用反向遗传学构建的RSV重组仙台病毒载体的免疫原性和保护效力进行了检查。RSV重组仙台病毒易于生长（即，在卵中达到极高的滴度），易于给药（鼻内滴剂），并增强B-和T-细胞应答，从而在小动物模型中保护免受RSV攻击。未修饰的仙台病毒目前正在临床试验中作为其密切相关的人类同源病毒（人类副流感病毒1型）的疫苗进行研究。仙台病毒可能被证明是一个非常有价值的疫苗平台，允许靶向重要的儿科呼吸道病原体（其中主要是RSV）的重组体。
Respiratory syncytial virus (RSV) is among the most important and serious pediatric respiratory diseases, and yet after more than four decades of research an effective vaccine is still unavailable. This review examines the role of the immune response in reducing disease severity; considers the history of RSV vaccine development; and advocates the potential utility of Sendai virus (a murine paramyxovirus) as a xenogenic vaccine vector for the delivery of RSV antigens. The immunogenicity and protective efficacy of RSV-recombinant Sendai virus vectors constructed using reverse genetics is examined. RSV-recombinant Sendai virus is easy to grow (i.e., achieves extremely high titers in eggs), is easy to administer (intranasal drops), and elicits both B- and T-cell responses leading to protection from RSV challenge in a small-animal model. Unmodified Sendai virus is currently being studied in clinical trials as a vaccine for its closely related human cognate (human parainfluenza virus type 1). Sendai virus may prove an enormously valuable vaccine platform, permitting the delivery of recombinants targeting important pediatric respiratory pathogens, RSV chief among them.